Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies

被引：77

作者：

Stuver, Robert ^{[1
]}

Shah, Gunjan L. ^{[2
]}

Korde, Neha S. ^{[3
]}

Roeker, Lindsey E. ^{[4
]}

Mato, Anthony R. ^{[4
]}

Batlevi, Connie L. ^{[1
]}

Chung, David J. ^{[2
]}

Doddi, Sital ^{[5
]}

Falchi, Lorenzo ^{[1
]}

Gyurkocza, Boglarka ^{[2
]}

Hamilton, Audrey ^{[1
]}

Lin, Ya-Hui ^{[5
]}

Jakubowski, Ann A. ^{[2
]}

Joffe, Erel ^{[1
]}

Landau, Heather L. ^{[2
]}

Lin, Richard J. ^{[2
]}

Mailankody, Sham ^{[3
]}

Palomba, M. Lia ^{[1
]}

Park, Jae H. ^{[4
]}

Perales, Miguel-Angel ^{[2
]}

Ponce, Doris M. ^{[2
]}

V. Ramanathan, Lakshmi ^{[5
]}

Salles, Gilles A. ^{[1
]}

Scordo, Michael ^{[2
]}

Seo, Susan K. ^{[6
]}

Shah, Urvi A. ^{[3
]}

Stein, Eytan M. ^{[4
]}

Straus, David ^{[1
]}

Usmani, Saad Z. ^{[3
]}

Young, James W. ^{[2
]}

Zelenetz, Andrew D. ^{[1
]}

Noy, Ariela ^{[1
]}

Vardhana, Santosha A. ^{[1
,7
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA

[3] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, 1275 York Ave, New York, NY 10021 USA

[4] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA

[5] Mem Sloan Kettering Canc Ctr, Dept Lab Med, 1275 York Ave, New York, NY 10021 USA

[6] Mem Sloan Kettering Canc Ctr, Infect Dis Serv, Div Subspecialty Med, New York, NY 10021 USA

[7] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA

来源：

CANCER CELL | 2022年 / 40卷 / 06期

关键词：

D O I：

10.1016/j.ccell.2022.05.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：590 / 591

页数：2

共 50 条

[1] Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants
Roe, Tiffany L.
Brady, Tyler
Schuko, Nicolette
Nguyen, Amy
Beloor, Jagadish
Guest, Johnathan D.
Aksyuk, Anastasia A.
Tuffy, Kevin M.
Zhang, Tianhui
Streicher, Katie
Kelly, Elizabeth J.
Kijak, Gustavo H.
MICROBIOLOGY SPECTRUM, 2023, 11 (02)
[2] The Efficacy and Safety of Tixagevimab/Cilgavimab (AZD7442) Against Sars-Cov-2 Omicron BA. 5 for Patients with Hematologic Malignancies
Lee, Yoo Jin
Jo, Jae-Cheol
Kim, Youjin
Kim, Hyunki
BLOOD, 2023, 142
[3] Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients
Laracy, Justin C.
Yan, Judy
Steiger, Samantha N.
Tan, Carrie A.
Cohen, Nina
V. Robilotti, Elizabeth
Fender, Jerome
Cohen, Sara
Korde, Neha
Lee-Teh, Melissa
Noy, Ariela
Oved, Joseph H.
Roeker, Lindsey E.
Shah, Gunjan
Babady, N. Esther
Kamboj, Mini
Seo, Susan K.
HAEMATOLOGICA, 2023, 108 (11) : 3058 - 3067
[4] Efficacy of Preexposure Prophylaxis with Monoclonal-Antibody AZD7442 (tixagevimab-cilgavimab) Against Sars-Cov2 Variants in Patients with CLL
Benjamini, Ohad
Tadmor, Tamar
Avigdor, Abraham
Gershon, Rotem
Klike, Limor
Atari, Nofar
Abdelkader, Bayan
Mandelboim, Michal
Rahav, Galia
BLOOD, 2022, 140 : 9900 - 9901
[5] Serum AZD7442 (tixagevimab-cilgavimab) concentrations and in vitro IC50 values predict SARS-CoV-2 neutralising antibody titres
Clegg, Lindsay E.
Stepanov, Oleg
Matthews, Sam
White, Tom
Seegobin, Seth
Thomas, Steven
Tuffy, Kevin M.
Nagard, Mats
Esser, Mark T.
Streicher, Katie
Cohen, Taylor S.
Aksyuk, Anastasia A.
CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2024, 13 (06)
[6] Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19
Levin, Myron J.
Ustianowski, Andrew
De Wit, Stephane
Launay, Odile
Avila, Miles
Templeton, Alison
Yuan, Yuan
Seegobin, Seth
Ellery, Adam
Levinson, Dennis J.
Ambery, Philip
Arends, Rosalinda H.
Beavon, Rohini
Dey, Kanika
Garbes, Pedro
Kelly, Elizabeth J.
Koh, Gavin C. K. W.
Near, Karen A.
Padilla, Kelly W.
Psachoulia, Konstantina
Sharbaugh, Audrey
Streicher, Katie
Pangalos, Menelas N.
Esser, Mark T.
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (23): : 2188 - 2200
[7] Association Between AZD7442 (Tixagevimab-Cilgavimab) Administration and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Hospitalization, and Mortality
Kertes, Jennifer
Ben David, Shirley Shapiro
Engel-Zohar, Noya
Rosen, Keren
Hemo, Beatriz
Kantor, Avner
Adler, Limor
Stein, Naama Shamir
Reuveni, Miri Mizrahi
Shahar, Arnon
CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : E126 - E132
[8] Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies
Chang, Andres
Koff, Jean L.
Lai, Lilin
Orellana-Noia, Victor M.
Surati, Minal
Leal, Alyssa M. K.
Ellis, Madison L.
Wali, Bushra
Moreno, Alberto
Linderman, Susanne L.
O'Leary, Colin B.
Allen, Pamela B.
Churnetski, Michael C.
Dhodapkar, Madhav, V
Suthar, Mehul S.
Cohen, Jonathon B.
Ahmed, Rafi
BLOOD ADVANCES, 2023, 7 (11) : 2459 - 2462
[9] Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS-CoV-2 Infection
Ignacio, Rachel A. Bender
Wohl, David A.
Arends, Rosalin
Reddy, Venkatesh Pilla
Mu, Ying
Javan, Arzhang Cyrus
Hughes, Michael D.
Eron, Joseph J.
Currier, Judith S.
Smith, Davey
Chew, Kara W.
Gibbs, Michael
Fletcher, Courtney, V
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (06) : 1207 - 1213
[10] Tixagevimab/cilgavimab (AZD7442/Evusheld) prevent from COVID19 in patients with hematologic malignancies under active chemotherapy
Lee, Yoo Jin
Kim, Hyun-Ki
Kim, Youjin
Park, Sang Hyuk
Lim, Ji-Hun
Jung, Jiwon
Choi, Yun-suk
Jo, Jae-Cheol
ANNALS OF HEMATOLOGY, 2024, 103 (07) : 2533 - 2539

← 1 2 3 4 5 →